Big new study in pediatric and young adult acute myeloid leukemia warns against ‘trickle-down therapeutics’
Dec. 11, 2017
| By Susan Keown / Fred Hutch News Service
Researchers found key differences between the molecular signatures of AML in patients of different ages: So why should we keep assuming that therapies developed for the elderly will work for the young?
Dr. Filippo Milano and colleagues in the Cord Blood Program at Fred Hutch have received funding from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation to support a clinical trial to improve the use of umbilical cord blood as a treatment for leukemia ... and more good news at Fred Hutch.
New research writes latest chapter in one drug's story
June 27, 2017
| by Susan Keown / Fred Hutch News Service
The leukemia drug gemtuzumab ozogamicin (Mylotarg) was pulled from the market seven years after initial approval. Now, new evidence may be bringing it back to life to treat a specific group of patients.
30 years after an early BMT, a cancer survivor pays it forward by helping researchers ‘make it better for others’
March 29, 2017
| By Diane Mapes / Fred Hutch News Service
The road to a cure was not easy for Mike Rubin, who underwent a bone marrow transplant in 1987. But 30 years after the lifesaving procedure, this survivor and Fred Hutch fundraiser is celebrating -- and paying it forward so others can do the same.
New technology allows scientists to peek inside nearly 70,000 cells in single experiment
Jan. 16, 2017
| By Sabrina Richards / Fred Hutch News Service
Researchers have developed a new technique which allows them to examine huge amounts of information from a single cell or zoom out and see data patterns among thousands upon thousands of cells — all in a single experiment. The method could help researchers dive deep into the ecosystem of cancer.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.